Kyverna Therapeutics
May 29, 2026 |
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on liberating patients with autoimmune diseases through the curative potential of cell therapy. Our lead candidate, miv-cel (mivocabtagene autoleucel, KYV-101), is a fully human, autologous, CD19-targeting CAR T-cell therapy under investigation for B-cell-driven autoimmune diseases.